Your Health, We Care
Release date: 2024-08-28 15:13:06 Recommended: 147
Balversa is a targeted drug targeting FGFR mutations for the treatment of advanced urothelial carcinoma, inhibiting cancer cell growth by inhibiting the FGFR signaling pathway, providing patients with a new treatment option.
When using Balversa, patients need to pay special attention to the following two points:
Balversa may have some effects on liver function, and during treatment, patients should have regular liver function tests, including monitoring of liver enzyme levels, to ensure liver health and detect and manage potential liver function abnormalities in a timely manner.
Some patients may have visual problems such as blurred vision and light sensitivity after taking Balversa. Patients should pay close attention to their visual changes and inform their doctor immediately if there is any abnormality so that appropriate measures can be taken to ensure the safety of the medication.
Patients should be aware of potential side effects when taking Balversa. In particular, it is necessary to be vigilant for the clinical manifestations of hematologic abnormalities, such as anemia and leukopenia, and seek medical attention immediately once found.
If a patient develops a hematologic abnormality after Balversa, the clinical manifestations may include:
Manifested as paleness, fatigue, dizziness, palpitations, and other symptoms. When anemia is severe, people may feel short of breath and even affect their ability to perform daily activities.
It may lead to a decrease in immune function and increase the risk of infection. People may be more likely to have symptoms such as colds and fevers, and infections may not be easy to control. When leukopenia is severe, it can also affect wound healing and other treatments, such as chemotherapy.
For hematologic abnormalities caused by Balversa, such as anemia and thrombocytopenia, patients should seek medical attention in time. Your doctor may adjust the dose of your medication, stop taking it, or take other treatments to reduce your symptoms.
If a patient develops a hematologic abnormality after taking Balversa, the following two measures can be taken:
Regularly monitor the blood routine, including hemoglobin, white blood cell count, and other indicators, once abnormalities are found, you should communicate with your doctor in time, adjust the dose of Balversa according to the severity of the disease, or suspend the medication until the blood system returns to normal.
Patients with anemia may be given supportive care such as blood transfusions, iron supplementation, or folic acid; In patients with leukopenia, infection should be prevented, and if necessary, whitening drugs may be used to promote leukopoiesis, as well as personal hygiene and nutritional support to improve immunity.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
